We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Review · July 20, 2021

Selecting Optimal Immunotherapy for Driver-Negative Metastatic NSCLC

Nature reviews. Clinical oncology

 

Additional Info

Nature reviews. Clinical oncology
Selecting the Optimal Immunotherapy Regimen in Driver-Negative Metastatic NSCLC
Nat Rev Clin Oncol 2021 Jun 24;[EPub Ahead of Print], MJ Grant, RS Herbst, SB Goldberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading